FDA approves first drug for eosinophilic granulomatosis with polyangiitis
The FDA expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease that causes vasculitis. This new indication provides the first FDA-approved therapy specifically to treat EGPA. December 12, 2017